General Announcement::Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules in Columbia

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-Feb-2022 15:59:51
Status
New
Announcement Sub Title
Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules in Columbia
Announcement Reference
SG220214OTHRSFDY
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
14/02/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules in Columbia.

Attachments

SGX_PR_14022022.pdf
Total size =782K